范德堡大学同BioReference实验室合作开展肿瘤测序研究

  今日，美国范德堡大学大学医学中心（Vanderbilt University Medical Center）表示，他们将同BioReference实验室合作开展癌症患者肿瘤特性分析研究。
  根据多年的合作协议，合作双方将开发出一种针对肿瘤和恶性血液病的新一代测序检测板，并且使其在2016年在临床肿瘤研究中投入使用，这种检测板预计将包含超过300个基因，同时还可以靶向SNPs、进行插入或缺失研究、靶向作用基因拷贝数变异（CNVs）以及对药物可控的基因组区域进行基因融合研究等。
  来自范德堡大学医学中心的研究者Mary Zutter在一份声明中表示，我们看到了将我们学校临床专业同BioReference新一代测序技术能力连接的机会，以此来开发敏感性、临床可用的基因组解决方案，BioReference实验室CEO Marc Grodman补充道，这项合作将帮助开发可用于小样本检测的高效检测手段。
  BioReference实验室是Opkp健康公司的分公司，公司基因运营部副总裁Robert Daber表示，这项合作将帮助研究人员开发其它多种诊断技术，目前我们在多种领域的基因解决策略上仍然没有满足需要，比如检测血浆中的药物耐受性标志物以及基于检测盘的微小残留疾病监测等。
  上个月，范德比尔特英格拉姆癌症中心已经将自己作为基础医学公司（Foundation Medicine）精密医学交流财团的创始成员了。（转化医学网360zhyx.com）
  以上为转化医学网原创翻译整理，转载请注明出处和链接！
转化医学网推荐的新闻阅读：

Vanderbilt Collaborates With BioReference Labs on Tumor Sequencing
Vanderbilt University Medical Center today announced a collaboration with BioReference Laboratories for tumor profiling in cancer care.

Under the terms of the multiyear agreement, the partners will develop a next-generation sequencing panel for tumors and hematologic malignancies, aiming to make it available in 2016 for use in clinical oncology. The panel is expected to comprise more than 300 genes and will target SNPs, insertions and deletions, CNVs, and gene fusions in regions of the genome that are druggable.

"We saw a unique opportunity to connect Vanderbilt's clinical expertise with BioReference's NGS capabilities in order to develop sensitive and clinically useful genomic solutions," Mary Zutter, assistant vice chancellor for integrative diagnostics at Vanderbilt, said in a statement. BioReference Labs CEO Marc Grodman added that the collaboration would aim to "provide cost-effective testing that is able to be run on small samples."

The organizations said in a statement that their researchers would also collaborate on several other diagnostic assays. "We see unmet needs for genomic solutions in areas such as detecting drug resistance markers in plasma and panel-based minimal residual disease monitoring," BioReference Labs VP of Genomic Operations Robert Daber said.

BioReference Laboratories is a subsidiary of Opko Health.           

Last month, the Vanderbilt-Ingram Cancer Center established itself as a founding member of Foundation Medicine's Precision Medicine Exchange Consortium.